European Economic Area: UK Membership

Debate between Anna Soubry and Jim Shannon

Monday 6th November 2017 Commons Chamber

[Jim Shannon]

I am a “glass half full” person. I look on the bright side of life, because that is what we should do. Some people have a “glass half empty” outlook, and they look at everything negatively, but I do not look at things in that way. I am positive about what we are doing, the way forward and the ability of our ministerial team to achieve what we want. We have to agree to differ about how some things will come together, and that is part of life.

[Anna Soubry]

I thank the hon. Gentleman, who is my friend, for giving way. Is he not extremely worried—even though he is a great optimist, as we have heard—about the real possibility of not getting a deal, especially in relation to customs? Northern Ireland needs a proper deal on customs, and there is every chance that we will not get it. That eventuality would be a really serious problem for Northern Ireland.

[Jim Shannon]

I thank the right hon. Lady—she is also my friend—for her intervention. I think we share the same wish to get a successful deal, although, with great respect, I do not share her fears about it. I am keen to get a deal.

In the short time I have left, I want to share some figures that I have been provided with, which call into question the matter of EEA membership on financial grounds alone. About 43% of UK exports in goods and services went to other EU countries—£240 billion out of £550 billion total exports. That share has generally been declining, since exports to other countries have increased at a faster rate. The EU’s share of the world economy has declined, too. In particular, the developing world has grown faster than the developed world. We have to be mindful of the opportunities in other parts of the world and expect to do better out of them. About 54% of our imports into the UK came from other countries in the EU in 2016. The world will continue to need our goods, and we will continue to need to buy goods from the rest of the world. It seems to me that to remain a member of the EEA would not be in our nation’s best financial interests.

Pubs Code Adjudicator

Debate between Anna Soubry and Jim Shannon

Thursday 10th March 2016 Commons Chamber

[Anna Soubry]

I could not agree more with my hon. Friend. It is the change of culture that is so important. We have all encountered similar examples in our constituencies; I, too, have fought to keep local pubs open. Unfortunately, I was not successful in one instance, although I was in another. It is about changing the atmosphere and making sure that pubcos act in a sensible and responsible manner, not just towards their tied tenants, but to the broader communities.

[Jim Shannon (Strangford) (DUP)]

I understand that the Royal Institution of Chartered Surveyors failed to respond to the Government’s request for clarification on rent assessment guidance, and has clearly laid out its position that it is against a parallel rent assessment through which a tenant can compare their tied rents and rewards with the rents and rewards of those who are not tied. Will the Minister confirm how the adjudicator reconciles his position with that of a professional body such as the RICS?

[Anna Soubry]

I hear what my hon. Friend says—he is my Friend, as he knows—but I can tell him that Paul Newby is going to be his own man. I was a member of a professional body, and the Bar Council often had a point of view that I personally completely disagreed with. Paul Newby is a good man and he will be his own man. He will be fair, and he comes with a huge skill set.

Bombardier: Job Losses (East Belfast)

Debate between Anna Soubry and Jim Shannon

Tuesday 1st March 2016 Commons Chamber

[Anna Soubry]

The hon. Lady snuck India in there as well, so she gives me a number of points to answer. I can tell her that this Government absolutely recognise the huge importance of the aerospace sector, which is why we have put in as much money as we have, matched of course by the sector itself. It is important that we understand how vital it is that we continue to trade with China, but we are also hugely alert to the fact that China is slowly beginning to develop its own aerospace industry. In the past, it has bought its aeroplanes from other countries, but it is no great surprise that the Chinese are looking to the great success of our aerospace industry. The fear is that they will seek to replicate it—I shall put it in that way. The hon. Lady can be assured that we will always make it clear that United Kingdom industry, especially manufacturing, is incredibly important to the success of this Government, because it is so important to the success of our economy. If we do not have a good economy, we cannot have the sort of taxes we need to make sure we have the sort of services we need. Let us be in no doubt that aerospace is incredibly important to us, which, as I say, is why we have done the work and made the investment.

My hon. Friend the Member for Belfast East made a good point about UKTI, and we will continue to promote Northern Ireland in all the work we do in promoting the United Kingdom. We will work to support the company’s export campaigns, and UK Export Finance also stands ready to support C Series aircraft sales. He will remember that we specifically talked about whether or not we could do some more work in making the point that the wings had been made in the United Kingdom, in Belfast. We should seize upon that, use that great technology and the huge respect those wings rightly have, and do—I was going to say a much better job, but I would rightly be reprimanded for that—some real work on making the point that they are made in Belfast. There is some more work we can do there with UKTI, and I am committed to taking that up.

While we are on the C Series passenger jet programme, let me say that it is a beautiful aircraft. I was given a model of one, although I almost did not need one because we can see that it is such a lovely aircraft. The company has reaffirmed its commitment to the C Series passenger jet programme and Belfast’s critical role in its delivery. As we know, on 17 February Air Canada signed a letter of intent for up to 75 C Series aircraft, which is a positive development for the programme. Along with the Northern Ireland Executive, we are fully committed to Bombardier’s C Series aircraft programme. We have jointly supported the wing development by committing £113.37 million of repayable launch investment, and we stand ready to provide export promotion and finance to support it. We will continue to work with Bombardier to support its sales campaigns, and, as I say, there is an awful lot more we can do by way of UKTI to take full advantage of this.

[Jim Shannon]

This is a very difficult subject to consider. One of the unfortunate casualties of the lay-offs is the apprenticeship scheme. I understand that the scheme will probably be cancelled because of the job losses. With that in mind, has the Minister had any discussions with the Minister for Employment and Learning in Northern Ireland to look at other opportunities? Perhaps there could be help for those apprentices who have done some time already and would like to do more. I accept that it is not the Minister’s responsibility, but will she consider taking a look at that matter?

[Anna Soubry]

I am really very grateful to the hon. Gentleman for that intervention. I do not think I knew that, and it concerns me hugely, as I am sure it will concern everybody on the Opposition Benches. There is something particularly cruel about an apprentice losing their job, especially as we know that these are highly skilled jobs. I am more than happy to take that matter away. As the hon. Gentleman will see, I have three people sitting in the Box taking notes, so we will definitely take that away, and if there is anything I can do to help, I absolutely will do it.

Business Transactions: Cash Retentions

Debate between Anna Soubry and Jim Shannon

Wednesday 27th January 2016 Westminster Hall

[Anna Soubry]

It could never be said that this Government would prevaricate in any way or seek to knock things into the long grass.

[Jim Shannon]

The Minister would never do that.

[Anna Soubry]

Never. I can absolutely assure the hon. Lady that I take the issue very seriously and know that we need to make progress. There are reasons why we would want some sort of retention, but not in a way that is onerous, particularly for small businesses. As I said earlier, Simon Bingham came to see me and gave me real-life examples of how some of the bigger companies effectively use retentions for their cash flow. The money can sit with them for year after year, and the small business takes a serious hit.

Oral Answers to Questions

Debate between Anna Soubry and Jim Shannon

Tuesday 15th December 2015 Commons Chamber

[Jim Shannon (Strangford) (DUP)]

The Minister referred earlier to moneys that have been set aside by the Government for research and development in the aerospace industry. In my constituency, 6,500 people are directly employed by Magellan and Bombardier, and double that number are subcontracted. What discussions has the Minister had with the Northern Ireland Assembly to ensure that we can be part of that research and development?

[Anna Soubry]

I have not had those discussions, but I am more than happy to hold them with the hon. Gentleman—he knows my door is always open, especially to him. I recognise the huge importance of Bombardier, and the role that it plays in his constituency and the whole of Northern Ireland.

Armed Forces (Service Complaints and Financial Assistance) Bill [Lords]

Debate between Anna Soubry and Jim Shannon

Monday 9th March 2015 Commons Chamber

[The Minister of State, Ministry of Defence (Anna Soubry)]

I pay tribute to the Defence Committee for its work, and to my hon. Friend the Member for Penrith and The Border (Rory Stewart) for his sensible comments. I also pay tribute to the hon. Member for Bridgend (Mrs Moon) for her long-standing work, and thank her for her contribution today. I am afraid I cannot thank her for everything, because she came to see me last week and gave me part of her very filthy cold; but, as ever, she spoke with great force, and rightly made it clear—as did my hon. Friend the Member for Penrith and The Border—that Members would be watching the ombudsman’s progress very carefully.

While I am confident that the hon. Lady and my hon. Friend will be back here on 10 May, I do not necessarily have the same confidence in my own return. However, I can tell them that, should I be in such a fortunate position thanks to the support of the people of Broxtowe, I too will be keeping an eye on the progress of the ombudsman, regardless of the Bench on which I find myself sitting. Of course, in an ideal world the ombudsman would not have to do any work at all. Would it not be marvellous if she had no work to do? Unfortunately, however, she will have a great deal of work to do, because we have a system that, as we know, is not performing as it should be.

When I had the great pleasure of visiting Northern Ireland and meeting my hon. Friend—as I now consider him to be—the Member for Strangford (Jim Shannon), we spoke about the Bill and about the complaints system. He reminded me earlier today of the genuine concern that he feels about delay. Under the existing system, we hear all too often from members of all three services that there is too much delay, and that there is no excuse for it.

There are sometimes good reasons for delay. It is in the nature of service life that it may not be possible to find a witness—or even a complainant—for some time, because members of the armed forces may be on operations for at least six months. Someone who is serving on a submarine will be literally out of contact for those six months, or longer. Delay may also be caused by the complexity of a case, especially if it relates to allowances or pensions. However, all too often it is clearly due to the attitude that is taken. Complainants may be told, “I am very busy. I have a lot of other things on my plate. We are putting together a group of people to build a hospital in Sierra Leone. It is a crisis. It is an emergency and it is not going to wait, but your complaint can wait.”

We must change that attitude. A good, expeditious system will deliver justice. I know many people fear that false complaints will be lodged, but an effective system will ensure that only right and just complaints are dealt with, and people will then begin to have confidence in the system.

[Jim Shannon]

I thank the Minister for accepting what we said in Committee, and for responding to it so positively. We felt that the delays were untenable and unfair, and were creating problems. Does the Minister think that the new system will enable people to have confidence in it, and to believe that, at long last, the delays will be reduced and they will be helped to secure the satisfaction that they seek?

[Anna Soubry]

I believe that if the Bill passes through all its remaining stages, of which there are not too many, and if we extend the remit of Nicola Williams, in whom we all have confidence, to create the role of the ombudsman—following the passing of amendments in Committee that the Government did not oppose—the system will be hugely improved, and people will have more confidence in it. It also sends out a very clear message to our armed forces that they have got to sharpen up now and absolutely make sure that when somebody makes a complaint, whether it is a more serious and more appalling bullying and harassment complaint—which mercifully are rare; we know there is nothing peculiar about our armed forces that means we have more such complaints than other professions or fields of work—or complaints about allowances or pay or whatever, it is taken seriously and is acted upon not only fairly and justly, but with all due diligence and expeditiously, so we do not have these delays.

Veterans (Support and Rehabilitation)

Debate between Anna Soubry and Jim Shannon

Wednesday 19th November 2014 Westminster Hall

[Jim Shannon]

The Minister talks about speaking directly to all the councils. Given that this comes from Westminster, is that something that she would do for Scotland, Wales and Northern Ireland? I think that it would be important that we did do that.

[Anna Soubry]

I intend to write to every single local authority, so that will include all the Welsh and all the Scottish authorities; I see no division there. However, I said, after the hon. Gentleman had to pop out of the Chamber, that I know the situation is different in Northern Ireland. We discussed that at length in the main Chamber. It was an excellent debate, and I look forward to my visit and all that I will learn.

I began this part of my speech by talking about Lord Ashcroft’s report, which looked specifically at the transition to civilian life. I think that I can sum the position up in this way; it is certainly a view that I share. It seems a bit perverse to say to someone on the day that they sign up, “We want you now to start thinking about the day you leave. Plan your service accordingly.” An 18 or 19-year-old will have some difficulty with that, but it is the standard that we seek to set. The view that we take is, “You are great when you sign up. That is obviously the case or we wouldn’t take you on. But by the time you come to leave the service, you will be even better, not only as a human being but because of the skills and the other things that we will give you.”

Military Covenant

Debate between Anna Soubry and Jim Shannon

Wednesday 22nd October 2014 Commons Chamber

[Anna Soubry]

I am more than happy for the record to be corrected. I am delighted that they came along. I had dealings with Edwin Poots, and if I may say so, I always found him very good in his role as Health Minister in Northern Ireland.

In Northern Ireland, we are beginning to see good delivery on the covenant. That was demonstrated by the fantastic support at Newtownards, where 25,000 people attended the Northern Ireland regional Armed Forces day event, and a further 10,000 lined the parade route through the town.

Lord Ashcroft’s report has been mentioned. “The Veterans’ Transition Review” highlighted that the majority of former service personnel go on to lead very successful civilian lives, begin new careers and enjoy good health. However, it also acknowledged that the vast amount of support available to former service personnel throughout the UK can always be improved. The Government have now published our response to Lord Ashcroft’s report. As ever, I pay tribute to him for the huge amount of work he did in compiling it. It provides coherent guidance on how to improve the transition process, and it has been hugely helpful.

For those who are not familiar with the detail of the report, I confirm that 20 of Lord Ashcroft’s recommendations are already in place in full or in part, 11 are being developed and another eight are being investigated. Specifically on Northern Ireland, he recommended that armed forces champions should be appointed to allow service leavers and veterans to claim their entitlements without fearing for their personal security. I must say that we have found no evidence that previous service in the armed forces was in any way preventing our ex-service personnel from accessing the services provided by Northern Ireland Departments.

I am delighted to confirm that from April 2015, each of what I believe are called super-councils—the new local authorities—will nominate both a non-elected official and a councillor to be members of the Reserve Forces and Cadets Association for Northern Ireland. That must be an indication that progress is being made. The councillor will also act as the local veterans champion. They will manage local sensitivities, where they arise, and enable political action at the appropriate level to ensure that cases are progressed satisfactorily. That is really good progress. We want all local authorities across the United Kingdom to have a local veterans champion, so Northern Ireland is leading the way. That is another example of the covenant in action.

There are three recommendations in Lord Ashcroft’s report that we are not taking forward. One of those is Northern Ireland-focused. We simply do not agree—although we are always listening—with his view that section 75 of the Northern Ireland Act 1998 should be amended. Some hon. Members have said that, from time to time, section 75 has held back the extension of the covenant measures to Northern Ireland, but we do not think that is the case. However, as I have said, I am going to go over to Northern Ireland and speak to people.

When we last discussed these matters, we reported that some 93% of the covenant measures—this is how we judge whether the covenant is beginning to work—applied in Northern Ireland and that 7% were yet to be met. We are making progress. In June this year, when he was the Minister of State in the Northern Ireland Office, my right hon. Friend the Member for South Leicestershire (Mr Robathan) updated the Northern Ireland Affairs Committee and advised it that

“practically all of the outstanding covenant measures now apply, or will soon do so, in Northern Ireland.”

It is particularly pleasing to note that the Northern Ireland Affairs Committee has endorsed the Government’s view that there is no need for section 75 to be amended. In its report of July 2013, the Committee stated that it was

“reassured that the Northern Ireland equality framework does not create a greater barrier to implementation of the Covenant in Northern Ireland than elsewhere in the UK. It is important this is understood by those involved in the delivery of services to the Armed Forces Community.”

I have no doubt that everyone in the Chamber will share our sincere hope that those reassurances will be communicated throughout Northern Ireland. Indeed, much of this debate will be communicated throughout Northern Ireland, so that everybody understands what the covenant is all about, which is ensuring that there is no disadvantage.

Despite some concerns, the covenant is not only alive and well in Northern Ireland, but is going from strength to strength. That is testimony to the widespread commitment to the armed forces covenant across communities. Despite the difficulties of Northern Ireland’s unique history and political situation, we have seen real achievements in its progress.

In addition to the veterans champions, a bid supporting the legacy co-ordinator’s post within the UDR and Royal Irish Aftercare Service, of which we have heard much, received £50,000 from the £35 million of LIBOR funding that we have made available. That funding meant that the role was extended for two years, offering support and advice to statutory and voluntary organisations and individuals covering a range of issues. The Ministry of Defence fully recognises the medical care needs of veterans, which is why it funds measures such as the aftercare service to work alongside the NHS in delivering high-quality support and care. The aftercare service’s continuing collaboration with 38 (Irish) Brigade and the Reserve Forces and Cadets Association has led to the identification of possible research studies in Northern Ireland on future armed forces covenant activities and the needs and concerns of the veteran community.

[Jim Shannon (Strangford) (DUP)]

The Minister has mentioned the cadets. Does she recognise the immense contribution of the cadets to better community relations across Northern Ireland? In parts of the Province, the take-up for the cadets is very high among communities that in the past would have been perceived as nationalist communities.

[Anna Soubry]

I absolutely agree. The cadets bring many bonuses to individuals and, as the hon. Gentleman identifies, across the communities. I commend that marvellous organisation to anyone with a youngster. It is a win-win all round.

To make the most of our whole welfare force we have set up a veterans support forum that brings together MOD representatives, all the service charities, and veterans support organisations, to pool information and resources and ensure that those in need can be sign-posted towards the most effective help. In a way, it is quite similar to the Confederation of Service Charities—Cobseo—in Great Britain, and it is great to bring people together in that way. I am also pleased to note that discussions are ongoing with Help for Heroes, Combat Stress, and the Forces in Mind Trust, which all do a great job, about expanding that work in Northern Ireland, and all are due to be present at the next meeting of the veterans support forum.

In future, as the old Administrations draw down we should mark, with thanks, their support for the armed forces, and as the political landscape of Northern Ireland changes, we must focus on sustaining our momentum. The reforms relating to public administration in Northern Ireland will undoubtedly bring governance challenges for the newly created super-councils in April 2015, and we look forward to building and developing new relationships, and underpinning the unique set of circumstances in the region. We should not be afraid to expand on existing provisions and relationships where it is practical so to do, while also being mindful of personal and community opinions about the armed forces, which have been shaped by generations of bitter conflict. If I may say so, we should always look to the future.

We have made good progress, but it does not stop there and work is being undertaken to investigate how to embed and sustain covenant activity throughout the country, and to ensure that members of the armed forces community can access the information and support the need in their local communities.

Organ Transplants

Debate between Anna Soubry and Jim Shannon

Wednesday 17th July 2013 Commons Chamber

[Anna Soubry]

As the hon. Lady has anticipated, I do not have the answer to that question in my brief, but I will make sure that she receives a proper answer.

Over the past five years, we have been strengthening the donation infrastructure by implementing the 14 recommendations of the organ donation taskforce, which were published in 2008. Is it not nice that in this sort of debate we can pay tribute to another Government of a different political persuasion? We are all united on this issue; it is not a party political issue and it is always a pleasure to take part in these sorts of debates.

The number of donor co-ordinators across the United Kingdom has nearly doubled. They are working closely with intensive care clinicians and families to identify potential donors and obtain consent. As I have said, it is difficult work but, goodness me, what a difference it can make when it is successful.

We have appointed clinical leads and established donation committees and chairmen in all trusts. This has driven improvement in hospitals, optimising the potential for organ donation. I am delighted that we have achieved an increase of 50% in organ donor rates and of 30% in transplant rates over the past five years, helping many more people to have the transplant that they so desperately need. We need to do more, however, to enable many more people like Natalie to receive the organ transplant that in many circumstances will save or enhance their life.

On 11 July, NHS Blood and Transplant published the new UK strategy for organ donation and transplantation. “Taking Organ Transplantation to 2020” sets the agenda for increasing organ donation and transplant rates to world-class standards over the next seven years by aiming to improve consent rates to organ donation to more than 80%—they are currently 57%—and transplant more organs and increase the number of people receiving an organ. The strategy calls for a revolution in public attitudes and behaviours, and emphasises the importance of individuals and families agreeing to donation. That important work needs to take place irrespective of someone’s background, ethnicity, religion, faith or whatever else. We need to ensure that more people in all parts of society sign up to donate their organs and that we are able to persuade people’s families to allow their organs to be donated upon death.

[Jim Shannon]

The Welsh Assembly has recently taken a decision on organ donation, which is a positive step. Is it the intention to consider having that system in England, because that might help the hon. Member for Stretford and Urmston (Kate Green) in her quest?

[Anna Soubry]

The Welsh Government have introduced legislation under which people will have to opt out. We need to work with the Welsh Government to ensure that that system works, because there are concerns about the effect it will have across the United Kingdom when one country has people opting out as opposed to opting in, as in the rest of the United Kingdom.

The independent organ donation taskforce examined the case for moving to an opt-out system in 2008 and its recommendation was against such a system. Spain had an opt-out system, but I think that it has now rejected it. In any event, it no longer has an opt-out system. I know that because I had a conversation with Spain’s Health Minister at a recent EU conference, as one does at such events, where people learn from each other, which is extremely useful. Spain has one of the highest uptake levels for organ donation and there is an awful lot that we can learn from it.

When people apply for a driving licence, they can now tick a box to sign up for organ donation. That has its value. I think we should take every opportunity to encourage people to donate. However, if people are applying for a driving licence, there will be a tendency to skip that box because they want to get on with filling in the form.

I will be quite frank. When I got this job, ITV ran an excellent campaign for about a week in which it encouraged its viewers to sign up to be donors. I suddenly realised that I did not have a donor card. I was informed by my brilliant officials that I did not need a donor card and that all I needed to do was go online. I went online and signed up extremely easily and quickly. I was highly impressed by that system. I would not have known about it if ITV had not run that campaign. There are many opportunities to encourage and positively enable people to sign up and donate.

I will keep an open mind on the opt-out system. We will look at what happens in Wales. We may well have a great deal to learn from it. It may be that that system, which the Welsh Government have great hopes for, will be successful and that, in looking at it, we will form a different view. It is important to keep all one’s options open.

As I was saying, NHS Blood and Transplant announced its new strategy on 11 July. It has a new chair who is full of vigour and who I am sure will do an extremely good job.

In conclusion, transplantation offers many people the opportunity of life and enhances the lives of many others. I am delighted that Natalie has had that opportunity and we all wish her a long, happy and healthy life. We have made significant progress over the past five years and we must thank all the families of donors for agreeing to or supporting donation and giving the gift of life at such a terrible time in their own lives. We want to build on that progress and increase our donation and transplantation rates up to 2020 to match the world-class performance in many other countries. There is no reason why we cannot do as well as the Spanish or even better. We will continue to monitor the procedures in the United Kingdom for the selection and allocation of organs, and to consider whether changes to the allocation of organs need to be made to ensure equity of access for all people on the national waiting list.

I hope that the hon. Member for Stretford and Urmston, whom I congratulate again on securing this debate, has been heartened by the points that I have made. If there are any questions that I have not answered, I will of course write to her, unless she wants to make a quick intervention before I finish. She seems content and I am grateful for that.

Question put and agreed to.

HPV Vaccine

Debate between Anna Soubry and Jim Shannon

Tuesday 2nd July 2013 Commons Chamber

[The Parliamentary Under-Secretary of State for Health (Anna Soubry)]

I congratulate my hon. Friend the Member for Finchley and Golders Green (Mike Freer) on securing the debate and bringing this important subject before the House. He speaks, as ever, with considerable knowledge and makes a powerful argument. I would not expect anything other than that from my hon. Friend.

I shall not rehearse the statistics on vaccination— they were well explained by my hon. Friend—and the success that it has had in its take-up among young women. It has been a success. Seven million doses have been given so far in the United Kingdom, and we have achieved one of the highest rates of HPV vaccine coverage in the world, with 87% of the routine cohort of girls completing the three-dose course in the 2011-12 academic year. That contrasts with 35% take-up in America. The very low take-up in America explains why America has extended the vaccination to boys as well as girls; it is only 35% in girls.

As my hon. Friend explained most ably, because of the high uptake of HPV vaccine among girls, it is argued correctly that many boys are indirectly protected against HPV-associated cancers, such as anal cancer and head and neck cancers, as transmission of the virus between girls and boys should be substantially lowered. But of course, my hon. Friend is making the point that it does not protect men who have sex with men, and men who have sex with women who have not had the vaccine.

[Jim Shannon]

In my intervention on the hon. Member for Finchley and Golders Green (Mike Freer), I made the point about conducting campaigns regionally and UK-wide. Has the Minister had any discussions with the Health Minister in Northern Ireland, for instance, or the Health Minister in Scotland to ensure that we have a UK-wide strategy to address this issue?

[Anna Soubry]

I am going to repeat everything that has been said, and I agree; that is a very important point. As my hon. Friend the Member for Finchley and Golders Green argues, the vaccine does not protect men who have sex with women who have not been vaccinated, because they may have been in a country where the vaccine was not available to them. So I completely take the point, which is well made, and ask my officials to take it back to the Department.

As hon. Members know, the Department of Health is advised on all immunisation matters by the Joint Committee on Vaccination and Immunisation—an independent expert advisory committee—and our HPV vaccination policies are accordingly based on the advice of the JCVI. When the committee considered the introduction of the HPV vaccine in relation to cervical cancer, it did not recommend the vaccination of boys because with high vaccine uptake among girls, as is the case in the UK, it is judged that there would be little benefit in vaccinating boys. With the high uptake of HPV vaccine among girls, we would expect many boys to be indirectly protected against vaccine-type HPV infections and associated diseases, including anal cancer, head and neck cancers and penile cancers. However, the JCVI recognises that under the current programme, the same protection may not be provided to men who have sex with men, and of course men who have sex with women who have not had the vaccination.

Oral Answers to Questions

Debate between Anna Soubry and Jim Shannon

Tuesday 11th June 2013 Commons Chamber

[Jim Shannon (Strangford) (DUP)]

When a patient is ill and visits their GP, they will do as the doctor orders. One hundred thousand people will die of lung cancer this year. When will the Government do as the doctor orders and bring in plain packaging for tobacco?

[Anna Soubry]

I refer my hon. Friend to answers that I have given beforehand. I know the great work that he does on lung cancer and I am pleased to see that, yet again, we will have a national campaign following the great success of the last one. We can talk further.

Oral Answers to Questions

Debate between Anna Soubry and Jim Shannon

Tuesday 26th February 2013 Commons Chamber

[Anna Soubry]

The hon. Gentleman makes a very good point. Our advice is clear and the chief medical officer continues to give this advice: women who are pregnant or trying to become pregnant should not drink alcohol. If they feel that they must drink it, they should drink one or two units once or twice a week, at the very most. Our advice is clear, but he makes a good point, and I am happy to discuss it with him further.

[Jim Shannon (Strangford) (DUP)]

Recent NHS figures show that £2.7 billion was spent on alcohol-related illnesses. Will the Minister consider a campaign across the whole of the United Kingdom, including the Northern Ireland Assembly and Northern Ireland as a region, to combat the issue of drinking during pregnancy?

[Anna Soubry]

That is a very good point. The overconsumption of alcohol, whether by a pregnant woman or not, greatly concerns the Government, and that is one reason we want to introduce a minimum unit price of 45p. It was a good point well made, and I am always happy to meet the hon. Gentleman to discuss the matter further.

Terminal Illness (Access to Medicines)

Debate between Anna Soubry and Jim Shannon

Wednesday 23rd January 2013 Westminster Hall

[Jim Shannon]

There are parts of the world where drugs can be made more cheaply, and they include India. The drugs in India are equal to those made in the USA, for example, but can be made more cheaply. Why do not we obtain those similar drugs, at a cheaper price, so that we can provide the relevant care, as my hon. Friend has suggested? We should take that on board.

[The Parliamentary Under-Secretary of State for Health (Anna Soubry)]

I hope that the hon. Gentleman will be interested to know that last week I went to India where I had that precise conversation with several organisations. We hope that a memorandum of understanding will emerge, involving the regulatory bodies with which I had meetings. The hon. Gentleman is right to point out that we can take advantage of the great work being done in India to produce medicines that are just as good as those made anywhere else, and often at a fraction of the price.

[Jim Shannon]

Those are the sort of responses we hope to hear, because they show that the Government are working. The Minister, as we knew she would, has come up with a practical, physical response, and is doing the things that we have been hoping will come out of the debate. I thank her for initiating the process she outlined, and for moving things forward.

I am pleased to support the hon. Member for The Cotswolds in his cause of drawing attention to motor neurone disease, cancer and other illnesses, so that a treatment path will not be simply a step along the road to the end of life, but may enhance the quality of life. Perhaps a successful treatment path can be developed. According to Empower: Access to Medicine,

“Speeding up the development and availability of drugs that treat life-threatening diseases would benefit everyone in society.”

I believe that too. Everyone present will know people whom new drugs could help. The current testing and development process is long, cumbersome and expensive. In fact, a recent report by the Office of Health Economics found that it takes five years, on average, after the launch of a new drug, to win NICE approval. That time scale can be more than doubled when the time taken for a new drug to go from the development stage through to phase 3 and beyond is added. As an example, no new drug has been approved for motor neurone disease since riluzole was approved 20 years ago. Are we happy to sit back and rely on that one drug, or should there be more research? We need more research; we need to fund it, and we need it to be made possible.

Currently, pharmaceutical companies do not have a financial incentive to invest in developing new drugs for rare or “orphan” diseases—I am being careful in my terminology—because of the small number of the population who are affected and the high and uncertain costs of the drug development process. The drug regulatory regime is therefore clearly having a significant impact on those with life-threatening and rare diseases.

Just yesterday, the shadow Secretary of State held a meeting on special commissioning. Five speakers introduced the issues. The gentleman who spoke on cystic fibrosis said that drugs are available only in certain parts of the United Kingdom. He is worried that we are setting an imbalance, which I have taken up with my colleague back home, Edwin Poots, the Minister of Health, Social Services and Public Safety, to ensure that cystic fibrosis drugs are available to sufferers when they need them not only in England, but in Northern Ireland, Scotland and Wales.

The panel hosted by the shadow Secretary of State outlined the need for drugs allocation. There was a guy representing HIV patients, and 100,000 people in the United Kingdom are receiving HIV drugs to prolong their life. The man who spoke yesterday has lived for 20 years with the drugs that are available, but are those drugs available across the whole United Kingdom?

--- Later in debate ---

[The Parliamentary Under-Secretary of State for Health (Anna Soubry)]

It is a pleasure, Mr Caton, to serve under your chairmanship. I congratulate my hon. Friend the Member for The Cotswolds (Geoffrey Clifton-Brown) on securing this debate on a subject of which he clearly has considerable knowledge. I thank other hon. Members who have spoken, and pay tribute to the work done by Empower: Access to Medicine, particularly that of Mr Les Halpin, who has been spoken about in glowing terms. I add my good wishes to him to those of my hon. Friends the Members for The Cotswolds and for Southport (John Pugh)—the latter is giving me a thumbs-up, as I remembered the correct name of his constituency. A great failing of mine is not to remember it. I hope that Mr Halpin is able to watch this debate, and I know that he and many others will want to read it.

If I may say so, the debate is a good example of Parliament at its absolute best. Yet again, there is a story in one of the papers criticising Members of Parliament for expenses properly incurred. If only the press, instead of printing another knocking story, would come along and listen to debates such as this when important issues are put into the public domain with care and considerable knowledge. As is often the case in such debates in Westminster Hall, there has been an outbreak of political unity. Political parties play no part in this issue, and Members properly ask the Government tough questions. I pay tribute again to my hon. Friend the Member for The Cotswolds because he is a pleasant thorn in the Government’s side, and properly so. He has raised and is championing an issue that a constituent brought to his attention, and is holding the Government to account.

I fear—well, I know—that I cannot answer all the questions that my hon. Friend and the hon. Member for Copeland (Mr Reed) have asked and, as is the usual rule, if I cannot do so, my excellent officials will provide written responses. The matter is not in my portfolio—I am not making excuses—so I am not particularly familiar with it, and I am grateful for the excellent briefing that has been provided by my officials. Perhaps I will be forgiven for reading out a large part of my speech, which I do not normally do because I like to look as though I understand everything I am speaking about, but the subject is important and technical.

I would like to take credit for the approval of Kalydeco, a drug for cystic fibrosis users, but it was the National Institute for Health and Clinical Excellence that gave approval for it to be prescribed. The only reason I know anything about it is because one of my constituents wrote to me. A cystic fibrosis campaigning group has quite properly been contacting Members of Parliament, urging them to make all the representations that they can about the benefits of the drug. A very small number of people will benefit, because it relates to those who have cystic fibrosis because of a particular genetic disorder, but it will undoubtedly revolutionise their lives. I was certainly pleased to see that it will now be available for prescription.

The development of new medicines is a long and expensive process, as we all agree. The Association of the British Pharmaceutical Industry estimates that only one in 5,000 researched new compounds receive regulatory authority approval, taking 10 to 12 years on average. That is the scale of the research and the difficulties, in many respects.

The life sciences industry is undergoing rapid change. The time and cost involved in developing new medicines is rising, and the old “big pharma” model of having thousands of highly paid researchers working on a pipeline of blockbuster drugs is declining. A new model of collaboration, about the outsourcing of research and early clinical trials on patients, has emerged. Many patients with serious or life-threatening illnesses, who understandably expect that they should be able to access the latest and most effective treatments, feel that regulatory procedures can hamper access.

Turning to life sciences strategy, this country has a strong history of drug discovery and development, and improving access to medicines has long been a Government priority. The “Strategy for UK Life Sciences” was launched in December 2011. Recognising the issues facing the life sciences, the 10-year strategy includes measures to support innovation and early-stage development. My right hon. Friend the Prime Minister published a progress report and refresh of the strategy only last month.

My hon. Friend talked about adaptive licensing, as did other hon. Members. I would like to set out the arrangements that we are putting in place for an adaptive licensing pilot programme, with the objective of advancing and maximising the potential of existing flexibilities in the drug licensing processes to improve public health and stimulate innovative drug development.

The Medicines and Healthcare products Regulatory Agency—I shall refer to it as the MHRA, as opposed to its otherwise very long name—has convened an expert group on innovation in the regulation of health care and agreed to a tripartite programme to take that work forward. It includes work at EU level on how the existing flexibilities in EU regulation can be used to bring forward innovative products; work at national level exploring options to help companies maximise the potential of existing drug licensing processes; and work at arm’s length from the MHRA and Government. The co-ordination of some other activities required for the pilot will be undertaken by the Centre for the Advancement of Sustainable Medical Innovation, including the exploration of suitable candidate products. However, pharmaceutical companies must come forward and nominate candidates for adaptive licensing.

Last year, we consulted on an early access scheme to make certain new and promising medicines available to patients in the UK before they are formally licensed. The MHRA is currently assessing the consultation responses. If introduced, the early access scheme would be designed for promising new medicines that will treat, diagnose or prevent life-threatening, chronic or seriously debilitating conditions without licensed treatment options. It would provide a scientific opinion from the MHRA on the benefits and risks of a new medicine about a year before the licensing process was completed. That additional information would assist both clinicians and patients in making treatment decisions in areas of unmet need, such as those described earlier by my hon. Friend. Both programmes are in a very early stage of development, as I think we all appreciate, and we will have more to say on that in the near future.

Turning to stratified medicines and genomics—I cannot pronounce it, but I am sure that Hansard will correct me if I get the word wrong—ongoing work on stratified medicines will improve our understanding of why groups of people with particular diseases respond differently to treatments. That point was very well made by my hon. Friend the Member for Southport. Our initiative to sequence 100,000 whole genomes from NHS patients will provide valuable information for researchers to gather new insights into health and disease and to develop new diagnostic tools and treatments.

Rare diseases are classified as conditions affecting no more than five in 10,000 people in the EU. Patients with rare conditions deserve the same quality, safety and efficacy in medicines as those with more common conditions. Since the pharmaceutical industry has little interest, under normal market conditions, in developing medicines intended for small numbers of patients, the EU offers a range of incentives to encourage the development of what are called “orphan” medicines in order to address the unmet clinical need.

Applications for the designation of orphan medicines are reviewed by the European Medicines Agency’s Committee for Orphan Medicinal Products—in its short form, the COMP. Via the MHRA, the UK takes an active role in the decision-making processes at the COMP, ensuring that applications for orphan drug designation are appropriately recognised and encouraging companies to develop their products further. Taking that one step further, I join the hon. Member for Strangford (Jim Shannon) in paying tribute to the research being undertaken at Queen’s university Belfast, and I know that many other universities throughout the whole United Kingdom are doing research into that sort of medicinal pharmaceutical advancement. They do not have some of the constraints of pharmaceutical companies, or perhaps the desire that some of those companies have to make a profit, so it is often universities that are best placed to do some of that invaluable research and development.

[Jim Shannon]

The work that is done at Queen’s university could not happen without partnership with the pharmaceutical groups, and clearly, they can use the partnerships to their advantage in creating new medicines. Partnerships are what life is very much about. A partnership is how we can work together to make it better, and that is a partnership that can work.

[Anna Soubry]

I am grateful for that intervention and I completely agree. It is great when we see business working with our universities on research. It can be highly productive and undoubtedly mutually beneficial, including to the rest of society, and that collaborative approach is much to be welcomed. It is fair to say that many universities, at first, had a bit of resistance to working with business, seeing it somehow as sullying themselves. However, over time they have recognised the absolute mutual benefit to both and, of course, that includes, should it be successful, a benefit to society.

Diabetes

Debate between Anna Soubry and Jim Shannon

Wednesday 9th January 2013 Westminster Hall

[Anna Soubry]

I am concerned about it. It is unacceptable. I have already held a meeting with my officials and they are making further inquiries. I discussed with Mr Dawson what was happening locally in CCGs, which is where this will make a difference, when we see the power of our doctors and other health professionals to commission services, and the power and influence that patients and sufferers of diabetes will have. I am told that NHS Diabetes has now identified a diabetic lead in every CCG. There is an opportunity, through the reforms, to ensure that we now deliver locally as we should. All hon. Members who have contributed to this debate have identified a failure in respect of good outcomes and good practice throughout the NHS, right through to local level. That needs to be, and is being, addressed as a matter of urgency.

I have been alerted to problems with glucose meters and pumps—various new advances in technology. Some of this excites me. However, I am still concerned if there is not the availability that there should be, right across the NHS, notably for all sufferers of diabetes 1.

[Jim Shannon]

It is not just about the provision of the insulin pumps; it is also about training. There are two facets to that.

[Anna Soubry]

Indeed. I was going to end this part of my speech by saying that my constituent, Mr Dawson, paid tribute to what he described as his brilliant diabetic nurse at the Queen’s medical centre in Nottingham. He highlighted, as the hon. Gentleman has done, that it is all well and good having wonderful, great technology, but if people have access to it they need, critically, the support to be able to use it themselves. We must ensure that they have the highest-quality support, not just from their GPs, but from diabetic nurses and others who are trained and specialise in this condition.

Diabetes is common and is increasing, as hon. Members have mentioned. It is estimated that, by 2025, 4 million people will have diabetes.

Polycystic Kidneys

Debate between Anna Soubry and Jim Shannon

Tuesday 6th November 2012 Commons Chamber

[Anna Soubry]

I absolutely agree with everything that my hon. Friend says. I was horrified to discover in a recent meeting that unfortunately in England we are not making the progress on organ donation that we should. It is a serious problem. We know that so many lives can be saved or seriously improved if people are good enough to indicate that they are willing, on their death, for their organs to be donated.

Let me go further and say this: of course I understand why, when somebody dies, the family struggle in their bereavement to give permission to allow the loved one’s organs to be donated. However, I urge people to do so, even in those very difficult situations. It is a most wonderful way to create a real legacy by enabling somebody literally to live on through someone else. If more people could, in those dark moments, see that, it would make a profound difference to improving, and indeed prolonging, lives.

[Jim Shannon]

I thank the Minister for her pertinent words about transplants. I understand that when people renew their driving licence there is a box they can tick if they want to be on a donor register for the rest of their life. It is a painless exercise that commits them for ever and provides the authority for all their bodily items to be transplanted. Given that it is so easy to tick that box, perhaps more of those who are renewing their licence should do so to say, “Yes, I want to be a donor.”

[Anna Soubry]

The ability to do that is a golden opportunity for people, and I wish they would take it. One of the problems, though, is that someone applying for a licence will think, “Well, I’m applying for a driving licence and I can’t deal with all that now; I’ll come back to it another day”, and unfortunately they do not return to it having got their driving licence.

I would very much welcome a serious look at how we can solve this problem by campaigning harder to ask people to tick the box, make their views known, and speak to their families. Each and every one of us should talk among our families about the things that we want on our death. I know that these are difficult subjects, but this is, as we all know, a wonderful legacy that people can leave which makes a huge difference to the quality and length of the lives that people could lead.

As provision could be improved with the introduction of evidence-based best practice guidance both at diagnosis and for the management of people with polycystic kidney disease, I will ask my officials to raise this with the appropriate agencies to see what further actions can be taken.

I pay tribute to the hon. Lady and all those who have contributed to this debate, and thank them for drawing attention to this specific and important disease area. I also congratulate those at PKD Charity on all their hard work. I look forward to meeting them and the hon. Lady to make sure that we raise the profile of polycystic kidney disease.

Question put and agreed to.